India Pharma Exports Rise 6.8 Percent in Q1 FY27 Amid Growing Global Demand

India sees pharmaceutical exports rise 6.8% in the first quarter of FY27, according to Pharmexcil, driven by strong overseas demand for generic medicines, strengthening India's reputation as a reliable source of affordable medicines worldwide.

Pharmexcil reports that the growth reflects increased shipments to Europe, Africa and Southeast Asia, where Indian firms are filling supply gaps left by tighter regulations in competing markets, positioning India as a rising pharmaceutical power in global markets.

U.S. Tariff Plan outlines a future generic drug tariff that could reach 100% within two years and 200% by 2029, a policy that could pressure Indian exporters and reshape trade flows, potentially affecting pricing and supply chains for U.S. hospitals.

Industry analysts warn that while short‑term export gains are positive, the looming U.S. duties may push Indian manufacturers to diversify markets, invest in higher‑value specialty drugs, or seek bilateral agreements to mitigate tariff impact, prompting the Indian government to seek exemptions or negotiate trade terms.